drugset

Drugs / Typhoid Conjugate vaccine

Follow last change May 2025 re-read 2 minutes ago

Typhoid Conjugate vaccine

also known as TCV · typhoid vaccine · Vi-DT · Vi-DT Typhoid Conjugate Vaccine · Vi-DT Vaccine

Developed for: salmonellosis
Investigated by: International Centre for Diarrhoeal Disease Research, Bangladesh · Massachusetts General Hospital · PT Bio Farma

Trials 2 · a red edge is where a trial was stopped

today NCT06455852 · not/applicable NCT03460405 · Ph 2

20192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 21 trial
Phase 2	NCT03460405	Jul 2018 → Dec 2019	—	PT Bio Farma	Completed	No outcome recorded
Phase not applicable1 trial
—	NCT06455852	Mar 2025 → Dec 2028 expected	cholera	Massachusetts General Hospital	Recruiting	No outcome recorded

Also used as a comparator or background therapy in 2 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/21 trial
Phase 1/2	NCT05480800 Comparator	Sep 2022 → Sep 2024	salmonellosis	GlaxoSmithKline	Completed	No outcome recorded
Phase 21 trial
Phase 2	NCT06879327 Background	May 2025 → Sep 2027 expected	malaria	PATH	Recruiting	No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

Field	Value	Cited text
Known as	Typhoid Conjugate vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06879327 ↗ 2 NCT05480800 ↗ NCT06455852 ↗
Known as	TCV	“The investigators will administer an OCV or typhoid vaccine (TCV) control and monitor antibody responses to identify better CoPs for cholera following both vaccination and...” NCT06455852 ↗
Known as	typhoid vaccine	“The investigators will administer an OCV or typhoid vaccine (TCV) control and monitor antibody responses to identify better CoPs for cholera following both vaccination and...” NCT06455852 ↗
Known as	Vi-DT	“Investigational vaccine used was Vi-DT and control was Vi-PS.” PMID 38297337 ↗ Feb 2024
Known as	Vi-DT Typhoid Conjugate Vaccine	“Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine” NCT03460405 ↗
Known as	Vi-DT Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03460405 ↗
Modality	Vaccine	“Vi-DT conjugate vaccine” PMID 38297337 ↗ Feb 2024